Fertility Control Flashcards
Contraception: Age Range:
- menache to menopause
- <18s:
- menopause -> retrospective
diagnosis - trans men + non-binary assigned
female at birth: if no
hysterectomy/bilateral
oophorectomy, with risk of
pregnancy
Female Physiology
insert diagram
Female Physiology
insert diagram
A surge in LH leads to final egg maturation and release.
The follicle left after ovulation transforms to the corpus luteum.
The corpus luteum produces both oestrogen and progesterone which negatively feedback on FSH and LH.
If pregnancy does not occur, the corpus luteum degenerates and circulating hormone levels decline.
Sustained higher levels of oestrogen and or progesterone negatively feedback on production of FSH and or LH and in turn decrease the stimulation and or release of developing follicles.
Female Contraceptive Hormones: Oestrogen: Effect:
- suppresses ovulation
Female Contraceptive Hormones: Progesterone: Effect:
- suppress ovulation
- reduces cilia activity in the
fallopian tube - increases volume + thickens
cervical mucous - thinning of endometrium
*progesterone creates a
hormonally driven barrier
Overview of Hormonal Contraceptives:
insert flowchart
Exogenous Contraception: CHC:
- combined hormonal
contraceptives - oestrogen and progesterone
- effective immediately D1-5 else 7
days
Exogenous Contraception: CHC: Efficacy:
- highly user dependent
- 99%-91%
Affected by:
- diarrohoea and vomiting
- weight
- drug interactions
Exogenous Contraception: CHC: Modes of Administration:
- pill
- patch
- vaginal ring
Exogenous Contraception: CHC: Benefits:
- reduces risk of ovarian,
colorectal and endometrial
cancer - predictable bleeding patterns
- reduced menstrual bleeding and
pain - management of PCOS,
endometriosis, premenstrual
syndrome and acne - reduced menopausal symptoms
- maintains bone density in
perimenopausal under 50 - rapid return to fertility
Exogenous Contraception: CHC: Risks:
- breast tenderness
- weight gain
- bloating
- libido changes
- irregular bleeding
- increased risk of breast and
cervical cancer - risk of venous and arterial
thromboembolism: 3x - risk of thromboembolism lower
than during pregnancy and
post-partum period
CHC: Questions to ask:
- factors increasing thrombotic
events: age, weight, smoking,
clotting disorder - not in breastfeeding women until
after 6 weeks
Exogenous Contraception: CHC: Administration:
- standard 21 days followed by
hormone free interval (HFI) of 7
days - tailored regimens also suitable
Exogenous Contraception: Progesterone-only Contraceptives:
- mode of action varies according
to mode of administration - alters cervical mucous and
endometrial thickening - some inhibit ovulation as
primary MoA - all are suitable for breastfeeding
women
Exogenous Contraception: Progesterone-only Contraceptive: Modes of Administration:
- pill (mini pill/POP)
- injection
- implant
- interuterine system (IUS)